Skip to main content
Premium Trial:

Request an Annual Quote

Seegene

Premium
Seegene launched this week a new Seeplex STD/HPV Test that detects Chlamydia trachomatis, Neisseria gonorrhea, as well as 14 high-risk and five low-risk human papillomaviruses in a single tube.
 
The company introduced this test “in an effort to encourage widespread STD screening to help slow the transmission of these infections and promote more responsive and effective patient care.”
 
Seegene said that current clinical STD and HPV screening procedures are not cost-efficient because a separate test is required for each indication. The company said that the cost to patients to get tested for all the indications on the Seeplex STD/HPV test will be $20.
 

“The new Seeplex STD/HPV diagnostic test enables healthcare providers to quickly, accurately, and cost-effectively determine most prevalent STD/HPV infections in patients,” the company claimed.

Filed under

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.